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Elevated plasma homocysteine levels (tHcy) have been consistently associated with the risk of ischemic stroke 
in observational studies.1 Moreover, experimental studies sug-
gest that increases in total homocysteine aggravates vascular 
disease.2 However, some clinical trials that investigated the 
benefit of lowering tHcy with B vitamins to reduce the risk 
of stroke have been negative.3–6 In contrast, a recent large 
primary prevention trial in China, the China Stroke Primary 
Background and Purpose—Elevated plasma homocysteine levels are associated with stroke. However, this might be a 
reflection of bias or confounding because trials have failed to demonstrate an effect from homocysteine lowering in stroke 
patients, although a possible benefit has been suggested in lacunar stroke. Genetic studies could potentially overcome these 
issues because genetic variants are inherited randomly and are fixed at conception. Therefore, we tested the homocysteine 
levels–associated genetic variant MTHFR C677T for association with magnetic resonance imaging–confirmed lacunar 
stroke and compared this with associations with large artery and cardioembolic stroke subtypes.
Methods—We included 1359 magnetic resonance imaging–confirmed lacunar stroke cases, 1824 large artery stroke cases, 
1970 cardioembolic stroke cases, and 14 448 controls, all of European ancestry. Furthermore, we studied 3670 ischemic 
stroke patients in whom white matter hyperintensities volume was measured. We tested MTHFR C677T for association 
with stroke subtypes and white matter hyperintensities volume. Because of the established association of homocysteine 
with hypertension, we additionally stratified for hypertension status.
Results—MTHFR C677T was associated with lacunar stroke (P=0.0003) and white matter hyperintensity volume (P=0.04), 
but not with the other stroke subtypes. Stratifying the lacunar stroke cases for hypertension status confirmed this 
association in hypertensive individuals (P=0.0002), but not in normotensive individuals (P=0.30).
Conclusions—MTHFR C677T was associated with magnetic resonance imaging–confirmed lacunar stroke, but not large 
artery or cardioembolic stroke. The association may act through increased susceptibility to, or interaction with, high 
blood pressure. This heterogeneity of association might explain the lack of effect of lowering homocysteine in secondary 
prevention trials which included all strokes.   (Stroke. 2016;47:646-651. DOI: 10.1161/STROKEAHA.115.011545.)
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Prevention Trial (CSPPT), which recruited only hypertensive 
patients, demonstrated a beneficial effect in reducing risk of 
stroke.7 Possible reasons for this conflicting evidence include 
insufficient stroke phenotyping particularly if homocysteine is 
a predominant risk factor for one type of stroke, dietary folate 
fortification reducing tHcy in populations in which trials have 
been performed, interactions between treatment and risk fac-
tors, and insufficient treatment duration.
A subtype-specific effect, with elevated homocysteine pri-
marily increasing risk for small vessel disease (SVD) stroke, 
has been suggested by both epidemiological data and secondary 
analysis of clinical trials. Case–control studies have suggested 
that elevated homocysteine is primarily a risk factor for lacunar 
stroke8,9 and that there may be heterogeneity even within this 
subtype, with strongest associations in those SVD cases with 
multiple lacunar infarcts and confluent leukoaraiosis on mag-
netic resonance imaging (MRI).10 Most previous clinical trials 
that investigated the benefit of lowering homocysteine studied 
stroke as a combined event lumping together all different eti-
ologies (ie, hemorrhage and ischemic and ischemic stroke sub-
types). A secondary analysis in the Vitamins to Prevent Stroke 
(VITATOPS) trial3 found a borderline treatment effect in patients 
with lacunar stroke (hazard ratio 0.80 (95% confidence interval 
[CI] 0.67–0.96)), whereas an MRI VITATOPS substudy found 
vitamin-lowering therapy was associated with reduced white 
matter lesion volume progression in patients with severe white 
matter lesions.11 A further possibility is that elevated homocys-
teine may interact with certain cardiovascular risk factors, and 
treatment effect may only be detected if these interactions are 
taken into account; of possible relevance, the positive CSPPT 
trial was only performed in hypertensive individuals.
Another possible explanation for the conflicting epidemio-
logical and clinical trial data is that the association between 
homocysteine and risk of ischemic stroke is a reflection of 
reverse causality or residual confounding, that is, elevated 
tHcy does not play a causal role in stroke pathogenesis but are 
merely noncausally associated with an increased risk of stroke. 
Genetic studies have the potential to overcome these issues 
by using genetic variants associated with elevated tHcy as a 
proxy for tHcy because the inheritance of genetic variants is 
random and not influenced by confounding factors. The most 
often studied genetic variant, showing the strongest association 
with increased tHcy, is the cytosine (C) to thymine (T) substi-
tution at position 677 of the methylene tetrahydrofolate reduc-
tase (MTHFR) gene (rs1801133).12–14 Case–control studies that 
investigated the association of the MTHFR C677T variant with 
stroke yielded inconsistent results, which is likely because of 
small sample sizes and the varying stroke phenotypes stud-
ied. Meta-analyses have produced conflicting results with an 
association reported between MTHFR and ischemic heart dis-
ease and stroke in one study but not with stroke in another.12,15 
Studies using detailed MRI-based stroke phenotyping have 
suggested the association may be confined to, or strongest in, 
patients with the lacunar stroke subtype.10
Based on the above data, we hypothesised that the 
MTHFR C677T variant may be a specific risk factor for SVD 
but not for other stroke subtypes. Lacunar infarcts are small 
and frequently not seen on computed tomography, and there-
fore, MRI is important for accurate diagnosis.16 Therefore, 
we determined whether the MTHFR polymorphism is associ-
ated with MRI-confirmed lacunar stroke. We compared these 
results with similar analyses from patients with cardioembolic 
and large artery stroke. In addition, we determined whether 
the same polymorphism was associated with MRI white mat-
ter hyperintensities, another marker of SVD. Because of the 
known association of hypertension with both tHcy and stroke, 
and in view of the positive results from the recent CSPPT 
study, we also stratified the analyses by hypertension status.
Methods
Stroke Populations
We included 1359 MRI-defined lacunar stroke cases from the UK 
young lacunar stroke DNA study, the Leuven Stroke Study (LSS), 
and the MRI-confirmed lacunar stroke collaboration (MCLSC), in-
cluding cohorts from the UK, Germany, Italy, and Australia (Table 
I in the online-only Data Supplement). Lacunar stroke was defined 
as a clinical lacunar syndrome17 with an anatomically corresponding 
lacunar infarct on MRI (subcortical infarct ≤15 mm in diameter). All 
MRI scans were centrally reviewed by one physician (H.S. Markus). 
Exclusion criteria were stenosis >50% in the extra- or intracranial 
cerebral vessels; cardioembolic source of stroke, defined accord-
ing to the Trial of Organization 10172 in Acute Stroke Treatment 
(TOAST) criteria18 as high or moderate probability; subcortical in-
farct >15 mm in diameter, as these can be caused by embolic mecha-
nisms (striatocapsular infarcts); any other specific cause of stroke 
(eg, lupus anticoagulant, cerebral vasculitis, dissection, monogenic 
forms of stroke, eg, cerebral autosomal-dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy [CADASIL]). Large-
artery and cardioembolic stroke cases were obtained from Genetic 
Risk Factors for Leukoaraiosis Study (GENESIS), LSS, MCLSC, 
and the Wellcome Trust Case Control Immunochip Consortium 
(WTCCC2-Immunochip), including cohorts from the UK, Germany, 
Belgium, Italy, Sweden, Poland, Austria, and Australia. Cases were 
classified into stroke subtypes according to the pathophysiological 
TOAST classification,18 using clinical assessment, as well as brain 
and vascular imaging where available. Hypertension was defined as 
prescription of antihypertensives before stroke or systolic blood pres-
sure >140 mm Hg or diastolic blood pressure >90 mm Hg >1 week 
post stroke. Fourteen thousand four hundred and forty-eight ancestry-
matched controls were obtained from the same geographical location 
as the cases in each group. A description and characteristics of all 
cohorts are given in Table I in the online-only Data Supplement.
White Matter Hyperintensity Volumes Population
The white matter hyperintensity (WMH) volume population 
(n=3670) was derived from the International Stroke Genetics 
Consortium (ISGC) WMH collaboration. This collaboration mea-
sured WMH volumes in patients with ischemic stroke from the UK, 
Italy, Belgium, Germany, Australia, and USA (Table II in the online-
only Data Supplement). Inclusion criteria were >18 years of age, 
self-reported European ancestry, and a diagnosis of ischemic stroke. 
Exclusion criteria were any other cause of white matter disease, in-
cluding CADASIL, vasculitis, and demyelinating and mitochondrial 
disorders. MRI scans were acquired as part of routine clinical practice 
for evaluation of ischemic stroke. Fluid-attenuated inversion recovery 
sequences were primarily used for leukoaraiosis analysis; however, 
in their absence, T2 sequences were used. All scans were quantita-
tively graded to obtain a WMH volume, which was normalized for 
intracranial volume. WMH volume was measured in the hemisphere 
contralateral to the infarct and doubled to obtain whole brain vol-
umes. Patients with bilateral nonlacunar infarcts were excluded. All 
neuroimaging analyses have been previously described.19
Genotyping
Direct genotyping of rs1801133 was performed in all cohorts except 
WTCCC2-Immunochip using commercially available arrays from 
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Affymetrix or Illumina. In WTCCC2-Immunochip, rs1801133 was 
imputed from the 1000 Genomes integrated variant set (March 2012) 
using IMPUTE v2.20 The SNP was imputed with high accuracy (impu-
tation info score =0.91). The SNP passed genotyping frequency thresh-
olds (>97%) and was in Hardy–Weinberg equilibrium in all groups. To 
control for population stratification, individuals were removed that did 
not segregate with Hapmap II European populations based on ancestry 
informative principal component analysis using EIGENSTRAT soft-
ware or multidimensional scaling in PLINK software, and ancestry-
informative covariates were included in all analyses.21,22
Statistical Analysis
In each cohort, logistic regression was performed to test for associa-
tion of MTHFR C677T with MRI-defined lacunar stroke, cardioem-
bolic stroke, and large artery stroke, assuming an additive model and 
adjusting for ancestry-informative principal components.
For each cohort, the association between WMH volume and 
MTHFR C677T was determined by performing linear regression of 
WMH volume on genotype dosages. Results across all cohorts were 
combined using a fixed-effects inverse variance weighted meta-anal-
ysis method. Subsequently, we repeated the analyses for MRI-defined 
lacunar stroke and WMH volume stratified by hypertension status.
We set our P value threshold for the main analyses to P<0.05 and 
then used a Bonferroni-corrected value (P=0.005) to assess signifi-
cance in secondary analyses.
Results
Stroke Analyses
MTHFR C677T was significantly associated with lacunar 
stroke (odds ratio [OR] 1.20, 95% CI 1.09–1.33; P=0.0003), 
but not with large-artery stroke (OR 1.01, 95% CI 0.93–1.08; 
P=0.88) or cardioembolic stroke (OR 1.03, 95% CI 0.96–1.11; 
P=0.44; Figure 1).
In the lacunar stroke cases, the association was most pro-
nounced in homozygotes (OR 1.48, 95% CI 1.20–1.84 for TT 
versus CC; P=0.0003 and OR 1.17, 95% CI 1.01–1.36 for CT 
versus CC; P=0.03).
The overall prevalence of hypertension in the lacunar 
stroke cases was 72.6%. There were no differences in the 
prevalence of hypertension according to MTHFR genotype 
(72.0% in CC, 73.4% in CT, and 71.2% in TT). Stratifying the 
lacunar stroke cases for hypertension status demonstrated the 
association of MTHFR C677T with lacunar stroke was present 
in hypertensives (OR 1.24, 95% CI 1.11–1.38; P=0.0002), but 
not in normotensives (OR 1.09, 95% CI 0.92–1.29; P=0.30). 
In hypertensive and normotensive cases separately, the asso-
ciation of MTHFR C677T with lacunar stroke was again most 
pronounced in homozygotes (Table).
WMH Volumes Analyses
MTHFR C677T was significantly associated with WMH volume 
(OR 1.06, 95% CI 1.01–1.11; P=0.04; Figure 2). In the second-
ary analyses in which we stratified by hypertension status, there 
was a borderline association for either hypertensive cases (OR 
1.06, 95% CI 1.00–1.13; P=0.05), although this did not pass the 
Bonferroni-corrected threshold, whereas there was no association 
in normotensive cases (OR 1.02, 95% CI 0.95–1.11; P=0.57).
Discussion
In the present study, we showed that the tHcy-associated 
genetic variant MTHFR C677T was associated with lacunar 
stroke risk and cerebral SVD, but not for large artery or car-
dioembolic stroke, and that this association was restricted to 
patients with hypertension. Thereby, this study supports the 
hypothesis that homocysteine is a risk factor for specifically 
SVD and not for the other stroke subtypes.
Previous genetic association studies linking homocys-
teine to ischemic stroke have produced conflicting results.15 
Such candidate studies may be influenced by publication bias, 
which is reduced in large multicentre GWAS studies. A recent 
analysis of 18 SNPs associated with tHcy reported equivocal 
results in 12 389 ischemic stroke cases (METASTROKE).23 
There was no association between any SNPs associated with 
tHcy and all ischemic stroke or large artery or cardioembolic 
subtypes, consistent with this study. However, one SNP was 
associated with lacunar stroke (rs9369898, MUT), but no 
association was found with the MTHFR polymorphism.
Our study is the first large-scale study to include MRI-
based phenotyping of lacunar stroke. The majority of stroke 
cases in previous studies have relied on CT brain imaging 
in combination of a diagnosis of a lacunar stroke syndrome. 
In ≤50% of cases, a clinical lacunar syndrome is caused by 
pathologies other than SVD.24
Figure 1. Forest plot for the association of MTHFR C677T with 
stroke subtypes. The size of the box is inversely proportional to 
the estimate variance of the effect estimator. GENESIS indicates 
Genetic Risk Factors for Leukoaraiosis Study; LSS, Leuven 
Stroke Study; MCLSC, magnetic resonance imaging–confirmed 
lacunar stroke collaboration; and WTCCC2-Immunochip, Well-
come Trust Case Control Immunochip Consortium.
 by guest on Septem
ber 26, 2016
http://stroke.ahajournals.org/
D
ow
nloaded from
 
Rutten-Jacobs et al  MTHFR C677T Genotype and Small Vessel Disease  649
Another possible reason for the conflicting results between 
different studies is dietary folic acid fortification in certain pop-
ulations. This was present in some cohorts in METASTROKE 
and might have attenuated any association with MTHFR 
C677T in METASTROKE.15 In the present study, folic acid 
fortification was not used in any of the included stroke cohorts, 
but was used in some of the included WMH volume cohorts. 
The association shown between MTHFR C677T and WMH 
volume in the present study might have been attenuated by the 
inclusion of these folic acid–fortified cohorts.
The SVD-specific effect of MTHFR C677T in the pres-
ent study might reflect the effects of increased tHcy in SVD 
patients with this genetic variant. Although we did not assess 
tHcy in the present study and, therefore, cannot draw conclu-
sions on this association in the present study, previous stud-
ies support this hypothesis of possible SVD-specific effect 
of increased tHcy. Secondary analyses of the VITATOPS 
trial suggested that homocysteine-lowering therapy may 
be associated with improved outcome in SVD (both lacu-
nar stroke and WMH) but not in other stroke subtypes.3 In 
the VITATOPS trial, in which lacunar stroke subtyping was 
largely based on a clinical stroke syndrome with computed 
tomography imaging, a borderline significant reduction in 
recurrent stroke occurred in patients with SVD; based on our 
results, one could hypothesise that this treatment effect might 
be stronger in MRI-confirmed lacunar stroke. Consistent with 
this specific effect in SVD are the results of an MRI sub-
study in 359 individuals from VITATOPS; although no asso-
ciation was found in the group as a whole, in a subanalysis 
of patients with MRI evidence of severe SVD at baseline, 
B vitamin supplementation was associated with a significant 
reduction in WMH volume change.11 Two meta-analyses on 
previous genetic association studies linking MTHFR with 
WMH on MRI could not confirm an association between 
MTHFR and WMH.25,26 Individual studies that were included 
in these meta-analyses had only small number of patients, and 
it was suggested that much larger studies would be needed 
to detect an association.25 In the present study, we included 
twice as many subjects as the largest study in the previous 
meta-analyses that assessed WMH on a dichotomous scale 
and three times as many subjects as the study that assessed 
WMH volume.
We found that the association of MTHFR C677T with 
lacunar stroke was restricted to hypertensive individuals. One 
possible explanation for this finding exclusively in hyperten-
sive individuals might be that the association acts through 
increased susceptibility to, or interaction with, high blood 
pressure. Interestingly, the recent large primary prevention 
CSPPT trial showed a benefit of homocysteine-lowering 
therapy in reducing stroke risk in hypertensive individuals 
from a population in which folic acid fortification was not 
occurring.7
The major strength of our study is the confirmation of all 
lacunar strokes by MRI and the relatively large sample size. 
Furthermore, the approach of using a genetic proxy for tHcy 
reduces the likeliness of reversed causality and residual con-
founding compared with previous observational studies. The 
relationship between tHcy and stroke in observational stud-
ies might be confounded by unmeasured or not adequately 
measured factors (eg, other dietary factors) that are causally 
associated with stroke. In contrast, genetic studies rely on the 
fact that genetic variants are fixed from conception and are not 
influenced by other traits.
Moreover, the stroke cohorts were derived from countries 
in which folic acid fortification was not implemented at the 
time of stroke, which maximized the chances of demonstrating 
an effect for MTHFR C677T. We also included an analysis of 
WMH volume in ischemic stroke patients. Stroke patients rep-
resent an enriched population in whom WMH are increased. It 
has been shown, however, that the genetic factors underlying 
Table.  Association Between MTHFR C677T Genotypes and 
MRI-Defined Lacunar Stroke
MTHFR Genotype OR P Value
All lacunar stroke
  CT vs CC 1.17 (95% CI 1.01–1.36) 0.03
  TT vs CC 1.48 (95% CI 1.20–1.84) 0.0003
Hypertensive lacunar stroke
  CT vs CC 1.19 (95% CI 1.01–1.40) 0.04
  TT vs CC 1.58 (95% CI 1.25–2.00) 0.0001
Normotensive lacunar stroke
  CT vs CC 1.07 (95% CI 0.84–1.37) 0.58
  TT vs CC 1.23 (95% CI 0.85–1.78) 0.28
CI indicates confidence interval; MRI, magnetic resonance imaging; and OR, 
odds ratio.
Figure 2. Forest plot for the association of MTHFR C677T with 
WMH. The size of the box is inversely proportional to the esti-
mate variance of the effect estimator. ASGC indicates Australian 
Stroke Genetics Collaborative; GENESIS, Genetic Risk Factors 
for Leukoaraiosis Study; ISGS, Ischemic Stroke Genetics Study; 
LSS, Leuven Stroke Study; MGH, Massachusetts General Hospi-
tal; SGUL, St Georges University of London; SWISS, Sibling with 
Ischemic Stroke Study; and WTCCC2, Wellcome Trust Case-
Control Consortium 2.
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WMH in ischemic stroke patients seem to be similar to those 
in population-based studies of WMH.19
A potential limitation of the present study is that we did 
not have independent replication cohorts available to vali-
date our findings, and therefore, future studies are warranted 
to confirm these interesting findings. Furthermore, although 
MTHFR C677T is strongly associated with tHcy in other stud-
ies,12,14 we could not also directly assess the association of 
tHcy with stroke subtype in the present study because tHcy 
measurements were not available in all of our cohorts.
In summary, we showed that MTHFR C677T was associ-
ated with lacunar stroke in hypertensive individuals, support-
ing a possible causal role for homocysteine in the pathogenesis 
of cerebral SVD. Our results suggest that any future trials 
investigating the benefit of lowering homocysteine in stroke 
patients should focus on the SVD subtype and that they should 
incorporate MRI-based diagnosis.
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Cohorts description 
UK Young Lacunar Stroke DNA Study (DNA Lacunar) 
DNA Lacunar is a multicentre cohort study, which constitutes a large DNA resource of 
young patients with well phenotyped lacunar stroke and stroke-free community controls. 
Between 2005 and 2012, 1030 white patients of European ancestry with lacunar stroke, aged 
< 70 years, were recruited from 72 specialist stroke centres throughout the UK. All patients 
underwent brain MRI, imaging of the carotid arteries and ECG. Echocardiography was 
performed when appropriate. All MRI’s and clinical histories were reviewed centrally by one 
experienced stroke physician. 
970 Unrelated Caucasian controls, free of clinical cerebrovascular disease, were obtained by 
random sampling from general practice lists from the same geographical location as the 
patients. Sampling was stratified for age and sex. 
 
MRI-confirmed ischemic stroke collaboration (MCISC) 
Wellcome Trust Case-Control Consortium 2 (WTCCC2)  
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. 
Stroke cases were recruited from three centres in the UK (St. George's University London, 
Oxford and Edinburgh) and one centre in Germany, University and Klinikum Großhadern, 
Ludwig-Maximilians-University, Munich 
WTCCC2-UK: The St George’s Stroke Study consecutively recruited ischemic stroke patients 
attending cerebrovascular services in London between 1995 and 2008. All patients had 
clinically relevant diagnostic workup performed, including brain imaging with computed 
tomography (CT) and/or magnetic resonance imaging (MRI) as well as ancillary diagnostic 
investigations including duplex ultrasonography of the carotid and vertebral arteries, 
echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests. The Oxford Vascular Study recruited patients with acute ischemic 
stroke or transient ischemic attack (TIA) with evidence of infarction on brain imaging 
between 2002 and 2008 as part of a population-based stud. All cases were phenotyped by one 
experienced stroke neurologist with review of original imaging. The Edinburgh Stroke Study 
prospectively recruited consecutive stroke inpatients and outpatients between 2002 and 2005. 
An experienced stroke physician assessed each patient as soon as possible after the stroke, 
prospectively recording demographic and clinical details, including vascular risk factors and 
results of brain imaging and other investigations 
WTCCC2-Germany: The Munich study recruited consecutively between 2002 and 2008, 
from a single Stroke Unit with a high rate of MR imaging (>80%) (n=1383). All subjects 
were over 18 years of age, of self-reported European ancestry and with a diagnosis of 
ischemic stroke classified according to TOAST by an experienced neurologist or stroke 
physician. All patients had brain imaging as well as ancillary diagnostic investigations where 
clinically relevant. 
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 
1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development 
study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort 
are available as a common control set for a number of genetic and epidemiological studies. 
For the German samples controls were Caucasians of German origin participating into the 
population KORAgen study (www.gsf.de/kora/en/english.html). This survey represents a 
gender- and age stratified random sample of all German residents of the Augsburg area and 
consists of individuals 25 to 74 years of age, with about 300 subjects for each 10-year 
increment. All controls were free of a history of stroke or transient ischemic attack. 
 
Besta Stroke Study (Milano) 
This study includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 
with stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR). Ischemic 
stroke cases, first ever or recurrent, confirmed on brain imaging, were selected for this study. 
An experienced stroke neurologist assessed all cases. 
 
Australian Stroke Genetics Collaborative (ASGC)  
Stroke cases comprised European-ancestry patients admitted to four clinical centres across 
Australia (The Neurosciences Department at Gosford Hospital, Gosford, New South Wales 
(NSW); the Neurology Department at John Hunter Hospital, Newcastle, NSW; The Queen 
Elizabeth Hospital, Adelaide; and the Royal Perth Hospital, Perth) between 2003 and 2008. 
Stroke was defined by WHO criteria as a sudden focal neurologic deficit of vascular origin, 
lasting more than 24 hours and confirmed by brain imaging. Other investigative tests such as 
electrocardiogram, carotid Doppler and trans-oesophageal echocardiogram were conducted to 
define stroke aetiology as clinically appropriate.  
 
Leuven Stroke Study 
Patients with cerebral ischemia, defined as a clinical stroke with imaging confirmation or a 
TIA with a new ischemic lesion on diffusion weighted MRI, who were admitted to the Stroke 
Unit of the University Hospitals in Leuven were enrolled. All patients underwent brain 
imaging and a standardized protocol including carotid ultrasound or CT angiography and 
cardiac examination (echocardiography and Holter monitoring) in all patients. 
Control individuals were selected from the same population and were either spouses of 
patients with multiple sclerosis, amyotrophic lateral sclerosis or stroke or healthy community 
dwelling subjects partially from the Leuven University Gerontology Database. Controls 
either confirmed they never had a stroke or TIA or responded negative to any item of the 
Verification of Stroke Free Status questionnaire. 
 
GENESIS 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2011-2013. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
WTCCC2-Immunochip 
 
Bio-Repository of DNA in Stroke (BRAINS): London 
The Bio-Repository of DNA in Stroke (BRAINS) is an international study recruiting highly 
phenotyped patients with stroke. For the purposes of the current work all patients were 
Caucasians. Diagnosis of stroke was confirmed using positive imaging (MRI or CT) and 
ischemic stroke subtypes were assigned using TOAST criteria, based on clinical, imaging and 
risk factor data. The cohort has been described in detail elsewhere (Yadav S, Schanz R, 
Maheshwari A, et al. Bio-Repository of DNA in stroke (BRAINS): a study protocol. BMC 
Med Genet 2011; 12: 34). 
 
Glasgow: Scotland 
Patients with ischemic stroke attending the cerebrovascular service of the Western Infirmary, 
Glasgow, were recruited between 1990 and 2004 as part of an ongoing study of genetic and 
circulating biomarkers in stroke. All patients underwent brain imaging and extracranial 
carotid ultrasound in accordance with a standard clinical protocol. The study was approved 
by the West Ethics Committee.  
 
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 
1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development 
study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort 
are available as a common control set for a number of genetic and epidemiological studies. 
 
Lund Stroke Register, Sweden 
Lund Stroke Register (LSR) since 2001 continuously enrolls patients aged 18 and older with 
first-ever stroke, living in the primary uptake area of Skane University Hospital, Lund. The 
study is mainly hospital-based but has a good coverage of the whole geographical 
population.28 All included patients are examined with CT/MR or autopsy of the brain. When 
clinically indicated, the patients are examined with ultrasound imaging of carotid arteries, 
echocardiography, and angiography. In this study, first-ever ischemic stroke patients from 
LSR between 2001 and 2004 were included. All patients were assessed by a neurologically 
trained physician regarding stroke type. Informed consent was obtained from all individuals 
or when they were not able to respond from their next-of-kin. The study was approved by the 
Ethics Committee of Lund University. Biobank services were performed at Region Skane 
Competence Centre (RSKC Malmo), Malmo University Hospital, Malmo, Sweden. 
 
Swedish Control Samples 
Controls for the Lund cases were provided by the Swedish SLE network. Controls were 
healthy blood donors from the geographical areas of Uppsala, Stockholm and Lund. The 
studies were approved by the regional ethics boards and all subjects gave their informed 
consent to participate. Genotyping of the Swedish control samples was performed at the 
SNP&SEQ technology platform in Uppsala, Sweden (www.genotyping.se). 
 
Munich: Germany 
Cases were consecutive European Caucasians recruited from a single dedicated Stroke Unit at 
the Department of Neurology, Klinikum Groβhadern, Ludwig-Maximilians-University, 
Munich. Ischemic stroke subtypes were determined according to TOAST criteria based on 
relevant clinical and imaging data. 
 
German control samples 
German healthy control individuals were obtained from the PopGen biobank [Krawczak et 
al., Community Genet 9:55-61, 2006]. Written, informed consent was obtained from all study 
participants and all protocols were approved by the institutional ethical review committee of 
the participating centre. The panel is a cross-sectional control cohort from the Kiel area in 
Northern Germany. More than 300 phenotypes were collected for the cohort and a 3-year 
follow has recently been completed. All data and biomaterials are accessible via the PopGen 
biobank. The Genotyping was part of the German National Genome Research Network 
(NGFN) GWAS initiative and performed by the Institute of Clinical Molecular Biology 
(Christian-Albrechts-University of Kiel). 
 
Poland:Krakow 
Patients were recruited in the stroke unit of the Jagiellonian University in Krakow, Poland (a 
single-center study). All stroke patients and controls were >18 years of age and were white. 
All patients had clinically relevant diagnostic workup performed, including brain imaging 
with computed tomography (CT) (100%) and/or magnetic resonance imaging (MRI) (8%) as 
well as ancillary diagnostic investigations including duplex ultrasonography of the carotid 
and vertebral arteries (85.2%), echocardiography (54.8%). MR-angiography, CT-angiography 
Holter monitoring, transesophageal echocardiography and blood tests for hypercoagulability 
were performed were indicated. Patients were classified into etiologic subtypes according to 
the Trial of Org 10172 in Acute Stroke Treatment (TOAST). 
The control group included unrelated subjects taken from the population of southern Poland. 
Control subjects had no apparent neurological disease based on the findings in a structured 
questionnaire and a neurological examination. The study was approved by local research 
ethics committees and informed consent was obtained from all participants. 
 
 
White Matter Hypertensities collaboration International Stroke Genetics Consortium 
 
St Georges University of London (SGUL) 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2007-2011. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
Massachusetts General Hospital (MGH) 
Cases presenting with ischemic stroke and admitted to the Massachusetts General Hospital 
(MGH) Stroke Unit through the Emergency Department, or evaluated in the MGH Neurology 
outpatient clinics, as well as on the inpatient Medical and Vascular Surgical services from 
January 2003 to July 2008. Ischemic stroke was defined as either (1) a radiographically 
proven (head CT or MRI) infarct associated with the appropriate clinical stroke syndrome, or 
(2) a fixed neurological deficit persisting more than 24 hours, consistent with a vascular 
pattern of involvement and without radiographic evidence of demyelinating or other non-
vascular disease. All subjects were evaluated by a neurologist upon presentation and clinical 
and laboratory data were collected during the admission for qualifying ischemic stroke event.  
All patients had acute brain imaging as well as ancillary diagnostic investigations: cervical 
and intracranial vessel imaging using CT or MR angiography (75%), cervical ultrasound 
(24%), echocardiography (86%), and Holter monitoring (16%).  
 
Ischemic Stroke Genetics Study (ISGS) 
Ischemic Stroke Genetics Study (ISGS) was a 5-center, prospective, case-control study of 
first-ever ischemic stroke cases in the United States. All affected individuals had WHO-
defined stroke confirmed by a study neurologist to be ischemic on the basis of head CT or 
brain MRI. Peripheral blood DNA samples were collected between May 2003 and September 
2008.  
 Sibling with Ischaemic Stroke Study (SWISS) 
This is a prospective, multicentre study of sibling pairs with first-ever or recurrent ischemic 
stroke. Probands were recruited from 70 clinical centres across the US and Canada. Ischemic 
stroke affected and unaffected siblings were recruited primarily using proband-initiated 
contact. All affected individuals had WHO-defined stroke confirmed by a study neurologist 
to be ischemic on the basis of brain imaging. Peripheral blood DNA samples were collected 
between October 2000 and December 2009.  
  
Appendix 
 
UK Young Lacunar Stroke DNA Study collaborators 
Study managers: Josie Monaghan; Alan Zanich, Samantha Febrey, Eithne Smith, Jenny 
Lennon, St George’s University of London 
 
Participating centres (number of enrolled patients per centre; local investigators): 
Aberdeen Royal Infirmary, Aberdeen (12; Mary Macleod). Addenbrooke’s Hospital, 
Cambridge (54; Jean-Claude Baron, Elizabeth Warburton, Diana J Day, Julie White). 
Airedale General Hospital, Steeton (4; Samantha Mawer). Barnsley Hospital, Barnsley (3; 
Mohammad Albazzaz, Pravin Torane, Keith Elliott, Kay Hawley). Bart’s and the London, 
London (2; Patrick Gompertz). Basingstoke and North Hampshire Hospital, Basingstoke (13; 
Elio Giallombardo, Deborah Dellafera). Blackpool Victoria Hospital, Blackpool (11; Mark 
O'Donnell). Bradford Royal Infirmary, Bradford (1; Chris Patterson). Bristol Royal 
Infirmary, Bristol (8; Sarah Caine). Charing Cross Hospital, London (12; Pankaj Sharma). 
Cheltenham General and Gloucester Royal Hospitals, Cheltenham and Gloucester (10; 
Dipankar Dutta). Chesterfield Royal Hospital, Chesterfield (4; Sunil Punnoose, Mahmud 
Sajid). Countess of Chester Hospital, Chester (22; Kausik Chatterjee). Derriford Hospital, 
Plymouth (4; Azlisham Mohd Nor). Dorset County Hospital NHS Foundation Trust, 
Dorchester (6; Rob Williams). East Kent Hospitals University NHS Foundation Trust, Kent 
(22; Hardeep Baht, Guna Gunathilagan). Eastbourne District General Hospital, Eastbourne 
(4; Conrad Athulathmudali). Frenchay Hospital, Bristol (1; Neil Baldwin). Frimley Park 
Hospital NHS Foundation Trust, Frimley (6; Brian Clarke). Guy’s and St Thomas’ Hospital, 
London (14; Tony Rudd). Institute of Neurology, London (25; Martin Brown). James Paget 
University Hospital, Great Yarmouth (1; Peter Harrison). King's College Hospital, London 
(16; Lalit Kalra). Leeds Teaching Hospitals NHS Trust, London (125; Ahamad Hassan). 
Leicester General Hospital and Royal Infirmary, Leicester (9; Tom Robinson, Amit Mistri). 
Luton and Dunstable NHSFT University Hospital, Luton (16; Lakshmanan Sekaran, 
Sakthivel Sethuraman, Frances Justin). Maidstone andTunbridge Wells NHS Trust (3; Peter 
Maskell). Mayday University Hospital, Croydon (14; Enas Lawrence). Medway Maritime 
Hospital, Gillingham (5; Sam Sanmuganathan). Milton Keynes Hospital, Milton Keynes (1; 
Yaw Duodu). Musgrove Park Hospital, Taunton (9; Malik Hussain). Newcastle Hospitals 
NHS Foundation Trust, Newcastle upon Tyne (12; Gary Ford). Ninewells Hospital, Dundee 
(5; Ronald MacWalter). North Devon District Hospital, Barnstaple (8; Mervyn Dent). 
Nottingham University Hospitals, Nottingham (17; Philip Bath, Fiona Hammonds). Perth 
Royal Infirmary, Perth (2; Stuart Johnston). Peterborough City Hospital, Peterborough (1; 
Peter Owusu-Agyei). Queen Elizabeth Hospital, Gateshead (5; Tim Cassidy, Maria Bokhari). 
Radcliffe Infirmary, Oxford (5; Peter Rothwell). Rochdale Infirmary, Rochdale (4; Robert 
Namushi). Rotherham General Hospital, Rotherham (1; James Okwera). Royal Cornwall 
Hospitals NHS Trust, Truro (11; Frances Harrington, Gillian Courtauld). Royal Devon and 
Exeter Hospital, Exeter (22; Martin James). Royal Hallamshire Hospital, Sheffield (1; 
Graham Venables). Royal Liverpool University Hospital and Broadgreen Hospital, Liverpool 
(9; Aravind Manoj). Royal Preston Hospital, Preston (18; Shuja Punekar). Royal Surrey 
County Hospital, Guildford (23; Adrian Blight, Kath Pasco). Royal Sussex County Hospital, 
Brighton (14; Chakravarthi Rajkumar, Joanna Breeds). Royal United Hospital, Bath (6; 
Louise Shaw, Barbara Madigan). Salford Royal Hospital, Salford (16; Jane Molloy). 
Southampton General Hospital, Southampton (1; Giles Durward). Southend Hospital, 
Westcliff-on-Sea (26; Paul Guyler). Southern General Hospital, Glasgow (34; Keith Muir, 
Wilma Smith). St George’s Hospital, London (108; Hugh Markus). St Helier Hospital, 
Carshalton (10; Val Jones). Stepping Hill Hospital, Stockport (4; Shivakumar 
Krishnamoorthy). Sunderland Royal Hospital, Sunderland (1; Nikhil Majumdar). The Royal 
Bournemouth Hospital, Bournemouth (15; Damian Jenkinson). The Walton Centre, Liverpool 
(15; Richard White). Torbay Hospital, Torquay (19; Debs Kelly). University Hospital 
Aintree, Liverpool (19; Ramesh Durairaj). University Hospital of North Staffordshire, Stoke-
on-trent (16; David Wilcock). Wansbeck General Hospital and North Tyneside Hospital, 
Ashington and North Shields (6; Christopher Price). West Cumberland Hospital, Whitehaven 
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Table I Stroke cohorts 
 
Cohort N Mean age (sd) % Male % Hypertensive 
DNA Lacunar & GENESIS     
Lacunar stroke 998 57.3 (9.6) 704 (71%) 705 (71%) 
Large artery stroke 64 70.1 (11.6) 44 (69%)  
Cardioembolic stroke 80 73.5 (14.6) 47 (59%)  
Controls 970 59.7 (4.3) 510 (53%) NA 
MCLSC     
Lacunar stroke 319 68.5 (11.8) 190 (60%) 262 (82%) 
Large artery stroke 1338 68.9 (11.9) 904 (68%) 906 (68%) 
Cardioembolic stroke 1094 73.7 (13.8) 558 (51%) 761 (70%) 
Controls 7623 62.5 (10.2) 4002 (52%) NA 
LSS      
Lacunar stroke 42 65.5 (13.9) 29 (69%) 26 (62%) 
Large artery stroke 70  43 (61%) 48 (69%) 
Cardioembolic stroke 157  96 (61%) 98 (62%) 
Controls 455 55.7 (14.5) 212 (47%) NA 
WTCCC2-Immunochip     
Large artery stroke 352 69.1 (12.2) 220 (62%) 234 (67%) 
Cardioembolic stroke 639 75.7 (11.8) 339 (53%) 417 (67%) 
Controls 5401  NA 2304 (43%) NA 
Abbreviations: DNA Lacunar, UK Young Lacunar Stroke DNA Study; GENESIS, Genetic Risk 
factors for Leukoaraiosis study; MCLSC, MRI-confirmed lacunar stroke collaboration; LSS, Leuven 
Stroke Study, WTCCC2-Immunochip, Wellcome Trust Case-Control Consortium II Immunochip  
Table II WMH study populations 
 
Centre Country N Mean age (sd) % Male % Hypertensive 
Milano Italy 151 57 (14) 60% 57% 
WTCCC2-Edinburgh UK 64 68 (13) 50% 72% 
WTCCC2-Munich FLAIR Germany 447 66 (12) 66% 72% 
WTCCC2-Munich T2 Germany 203 67 (12) 55% 67% 
WTCCC2-Oxford Flair UK 65 65 (15) 54% 65% 
WTCCC2-Oxford T2 UK 75 67 (13) 59% 68% 
WTCCC2-SGUL UK 323 70 (14) 63% 77% 
GENESIS 1  UK 121 67 (14) 67% 62% 
GENESIS 2 UK 228 69 (15) 58% 76% 
SGUL 1 UK 70 70 (13) 61% 61% 
SGUL 2 UK 57 68 (14) 58% 72% 
DNA Lacunar UK 303 57 (9) 72% 68% 
LSS Belgium 361 66 (15) 58% 59% 
MGH-Affymetrix US 476 67 (14) 60% 64% 
MGH-Omni US 84 64 (15) 63% 68% 
MGH-Illumina US 228 66 (15) 64% 61% 
ASGC Australia 96 65 (13) 57% 77% 
ISGS US 207 68 (14) 62% 61% 
SWISS US 111 66 (11) 48% 74% 
Overall   3670       
Abbreviations: Milano, Besta Stroke Register; WTCCC2, The Wellcome Trust Case-Control 
Consortium II; GENESIS, Genetic Risk factors for Leukoaraiosis study; SGUL, St Georges 
University of London; DNA Lacunar, UK Young Lacunar Stroke DNA Study; LSS, Leuven Stroke 
Study; MGH, Massachusetts General Hospital; ASGC, Australian Stroke Genetics Collaborative; 
ISGS, Ischemic Stroke Genetics Study; SWISS, Sibling with Ischaemic Stroke Study  
 
